Given that the Phase I clinical trial in IPF demonstrated a reduction of senescent cells and SASP within eleven days after a single treatment of D+Q, and improvements in physiological outcomes after 10 weeks (105), we reasoned that a three-month period would provide important feasibility, compliance and efficacy data, as well as potentially reveal other cognitive and biomarker effects useful for designing a larger study
Metabolic interplay between peroxisomes and other subcellular organelles including mitochondria and the Endoplasmic reticulum
CRIP1: Cysteine-rich intestinal protein 1
Because peptide effects depend on precise dosing, timing, and individual hormone baselines, a medically supervised, personalized protocolincluding comprehensive sleep histories, hormone panels, and lifestyle assessmentsis essential to maximize benefits while minimizing sideeffects and ensuring safety
A comparative analysis found that non-diabetic patients with obesity on tirzepatide had a 64% lower risk of developing new-onset gastroparesis compared to those on semaglutide
